Steven C Wallis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3541216/publications.pdf

Version: 2024-02-01

94433 88630 5,519 138 37 70 citations h-index g-index papers 139 139 139 4064 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Microsampling to support pharmacokinetic clinical studies in pediatrics. Pediatric Research, 2022, 91, 1557-1561.	2.3	6
2	Population Pharmacokinetics of Vancomycin in Critically III Adult Patients Receiving Extracorporeal Membrane Oxygenation (an ASAP ECMO Study). Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0137721.	3.2	7
3	<i>In vitro</i> effect of synovial fluid from patients undergoing arthroplasty surgery on MRSA biofilm formation. Journal of Antimicrobial Chemotherapy, 2022, 77, 1041-1044.	3.0	2
4	Evaluation of low-volume plasma sampling for the analysis of meropenem in clinical samples. Analytical and Bioanalytical Chemistry, 2022, 414, 2155-2162.	3.7	7
5	Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against Pseudomonas aeruginosa for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model. Antibiotics, 2022, 11, 101.	3.7	4
6	Innovation in microsampling for therapeutic drug monitoring of gentamicin in neonates: a proof-of-concept study. International Journal of Antimicrobial Agents, 2022, 59, 106513.	2.5	1
7	Oral fosfomycin activity against <i>Klebsiella pneumoniae</i> in a dynamic bladder infection <i>in vitro</i> model. Journal of Antimicrobial Chemotherapy, 2022, 77, 1324-1333.	3.0	6
8	Population Pharmacokinetics and Dosing Simulations of Ceftriaxone in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (An ASAP ECMO Study). Clinical Pharmacokinetics, 2022, 61, 847-856.	3.5	8
9	Use of the Hollow-Fiber Infection Model to Measure the Effect of Combination Therapy of Septic Shock Exposures of Meropenem and Ciprofloxacin against Intermediate and Resistant Pseudomonas aeruginosa Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2022, , e0214021.	3.2	O
10	Caspofungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-Abdominal Infections: A Prospective Cohort Study. Clinical Pharmacokinetics, 2022, 61, 673-686.	3.5	3
11	Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model. Microbiology Spectrum, 2022, 10, e0052522.	3.0	4
12	Population pharmacokinetics of ciprofloxacin in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study). Anaesthesia, Critical Care & Diamonth Medicine, 2022, 101080.	1.4	3
13	Multicenter Population Pharmacokinetic Study of Unbound Ceftriaxone in Critically III Patients. Antimicrobial Agents and Chemotherapy, 2022, 66, e0218921.	3.2	8
14	Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum \hat{l}^2 -lactamase-producing and non-producing <i>Escherichia coli</i> clinical isolates in a hollow-fibre infection model. Journal of Antimicrobial Chemotherapy, 2022, 77, 2448-2455.	3.0	3
15	Optimal dosing of cefotaxime and desacetylcefotaxime for critically ill paediatric patients. Can we use microsampling?. Journal of Antimicrobial Chemotherapy, 2022, 77, 2227-2237.	3.0	1
16	Pharmacodynamic evaluation of piperacillin/tazobactam against extended-spectrum \hat{l}^2 -lactamase-producing versus non-producing Escherichia coli in a hollow-fibre infection model. International Journal of Antimicrobial Agents, 2022, , 106623.	2.5	1
17	Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Meropenem in Neurocritical Care Patients: a Prospective Two-Center Study. Antimicrobial Agents and Chemotherapy, 2022, 66, .	3.2	5
18	The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study. Clinical Infectious Diseases, 2021, 72, 1369-1378.	5.8	85

#	Article	IF	CITATIONS
19	Population Pharmacokinetics of Levetiracetam in Patients with Traumatic Brain Injury and Subarachnoid Hemorrhage Exhibiting Augmented Renal Clearance. Clinical Pharmacokinetics, 2021, 60, 655-664.	3.5	16
20	A Loading Micafungin Dose in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration or Continuous Venovenous Hemodiafiltration: A Population Pharmacokinetic Analysis. Therapeutic Drug Monitoring, 2021, 43, 747-755.	2.0	3
21	Evaluation of Meropenemâ€Ciprofloxacin Combination Dosage Regimens for the Pharmacokinetics of Critically III Patients With Augmented Renal Clearance. Clinical Pharmacology and Therapeutics, 2021, 109, 1104-1115.	4.7	16
22	Pharmacodynamic Evaluation of a Single Dose versus a 24-Hour Course of Multiple Doses of Cefazolin for Surgical Prophylaxis. Antibiotics, 2021, 10, 602.	3.7	2
23	Development and validation of a UHPLC-MS/MS method to measure cefotaxime and metabolite desacetylcefotaxime in blood plasma: a pilot study suitable for capillary microsampling in critically ill children. Analytical and Bioanalytical Chemistry, 2021, 413, 4483-4491.	3.7	2
24	Prospective Cohort Study of Micafungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-abdominal Infections. Antimicrobial Agents and Chemotherapy, 2021, 65, e0230720.	3.2	4
25	Pharmacodynamics of once-versus twice-daily dosing of nebulized amikacin in an in vitro Hollow-Fiber Infection Model against 3 clinical isolates of Pseudomonas aeruginosa. Diagnostic Microbiology and Infectious Disease, 2021, 100, 115329.	1.8	2
26	Population Pharmacokinetics of Piperacillin and Tazobactam in Critically III Patients Receiving Extracorporeal Membrane Oxygenation: an ASAP ECMO Study. Antimicrobial Agents and Chemotherapy, 2021, 65, e0143821.	3.2	9
27	Pharmacokinetics of fluconazole and ganciclovir as combination antimicrobial chemotherapy on ECMO: a case report. International Journal of Antimicrobial Agents, 2021, 58, 106431.	2.5	5
28	Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study). International Journal of Antimicrobial Agents, 2021, 58, 106466.	2.5	12
29	A validated LC-MS/MS method for the simultaneous quantification of the novel combination antibiotic, ceftolozane–tazobactam, in plasma (total and unbound), CSF, urine and renal replacement therapy effluent: application to pilot pharmacokinetic studies. Clinical Chemistry and Laboratory Medicine. 2021, 59, 921-933.	2.3	4
30	The pharmacokinetics of meropenem and piperacillin-tazobactam during sustained low efficiency haemodiafiltration (SLED-HDF). European Journal of Clinical Pharmacology, 2020, 76, 239-247.	1.9	5
31	Cerebrospinal Fluid Penetration of Ceftolozane-Tazobactam in Critically Ill Patients with an Indwelling External Ventricular Drain. Antimicrobial Agents and Chemotherapy, 2020, 65, .	3.2	15
32	Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against Pseudomonas aeruginosa in a Dynamic <i>In Vitro</i> Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	7
33	Ticarcillin and piperacillin adsorption on to polyethersulfone haemodiafilter membranes in an ex-vivo circuit. International Journal of Antimicrobial Agents, 2020, 56, 106058.	2.5	4
34	Ceftolozane–tazobactam in an elastomeric infusion device for ambulatory care: an in vitro stability study. European Journal of Hospital Pharmacy, 2020, 27, e84-e86.	1.1	15
35	Clinically Relevant Epithelial Lining Fluid Concentrations of Meropenem with Ciprofloxacin Provide Synergistic Killing and Resistance Suppression of Hypermutable Pseudomonas aeruginosa in a Dynamic Biofilm Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	7
36	An Integrated Dialysis Pharmacometric (IDP) Model to Evaluate the Pharmacokinetics in Patients Undergoing Renal Replacement Therapy. Pharmaceutical Research, 2020, 37, 96.	3.5	10

#	Article	IF	Citations
37	Pharmacokinetics of Sulfamethoxazole and Trimethoprim During Venovenous Extracorporeal Membrane Oxygenation: A Case Report. Pharmacotherapy, 2020, 40, 713-717.	2.6	1
38	Low levels of salicylic acid and salicyluric acid are present in synovial fluid of patients taking aspirin at the time of knee arthroplasty surgery. Clinical and Experimental Pharmacology and Physiology, 2020, 47, 1635-1637.	1.9	2
39	Comparative Plasma Pharmacokinetics of Ceftriaxone and Ertapenem in Normoalbuminemia, Hypoalbuminemia, and Albumin Replacement in a Sheep Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	4
40	Conventional Pig as Animal Model for Human Renal Drug Excretion Processes: Unravelling the Porcine Renal Function by Use of a Cocktail of Exogenous Markers. Frontiers in Pharmacology, 2020, 11, 883.	3 . 5	14
41	Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2020, 75, 2633-2640.	3.0	12
42	Prophylactic Cefazolin Dosing in Women With Body Mass Index >35 kg·mâ^2 Undergoing Cesarean Delivery: A Pharmacokinetic Study of Plasma and Interstitial Fluid. Anesthesia and Analgesia, 2020, 131, 199-207.	2.2	14
43	Population pharmacokinetics of ticarcillin in critically ill patients receiving extended daily diafiltration. International Journal of Antimicrobial Agents, 2019, 54, 351-355.	2.5	2
44	Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	35
45	Pharmacokinetics of Total and Unbound Cefazolin during Veno-Arterial Extracorporeal Membrane Oxygenation: A Case Report. Chemotherapy, 2019, 64, 115-118.	1.6	4
46	Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients. Critical Care, 2019, 23, 205.	5.8	22
47	Analysis of capillary microsamples obtained from a skin-prick to measure vancomycin concentrations as a valid alternative to conventional sampling: A bridging study. Journal of Pharmaceutical and Biomedical Analysis, 2019, 169, 288-292.	2.8	12
48	In-vitro adsorption and sieving coefficient of ticarcillin-clavulanate during continuous haemofiltration. International Journal of Antimicrobial Agents, 2019, 54, 261-264.	2.5	7
49	Defining optimal dosing of ciprofloxacin in patients with septic shock. Journal of Antimicrobial Chemotherapy, 2019, 74, 1662-1669.	3.0	18
50	Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2019, 64, .	3 . 2	21
51	A validated LC-MSMS method for the simultaneous quantification of meropenem and vaborbactam in human plasma and renal replacement therapy effluent and its application to a pharmacokinetic study. Analytical and Bioanalytical Chemistry, 2019, 411, 7831-7840.	3.7	11
52	A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration. Antimicrobial Agents and Chemotherapy, 2019, 64, .	3.2	21
53	Lung Pharmacokinetics of Tobramycin by Intravenous and Nebulized Dosing in a Mechanically Ventilated Healthy Ovine Model. Anesthesiology, 2019, 131, 344-355.	2.5	17
54	Population Pharmacokinetics of Periarticular Ketorolac in Adult Patients Undergoing Total Hip or Total Knee Replacement Surgery. Anesthesia and Analgesia, 2019, 129, 701-708.	2.2	6

#	Article	IF	CITATIONS
55	Evidence of clinical response and stability of Ceftolozane/Tazobactam used to treat a carbapenem-resistant Pseudomonas Aeruginosa lung abscess on an outpatient antimicrobial program. International Journal of Antimicrobial Agents, 2018, 51, 941-942.	2.5	9
56	Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	21
57	Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	17
58	Characterisation of 40†mg/ml and 100†mg/ml tobramycin formulations for aerosol therapy with adult mechanical ventilation. Pulmonary Pharmacology and Therapeutics, 2018, 50, 93-99.	2.6	4
59	Clinical application of microsampling versus conventional sampling techniques in the quantitative bioanalysis of antibiotics: a systematic review. Bioanalysis, 2018, 10, 407-423.	1.5	25
60	Maximally effective dosing regimens of meropenem in patients with septic shock. Journal of Antimicrobial Chemotherapy, 2018, 73, 191-198.	3.0	40
61	A UHPLC–MS/MS method for the simultaneous determination of piperacillin and tazobactam in plasma (total and unbound), urine and renal replacement therapy effluent. Journal of Pharmaceutical and Biomedical Analysis, 2018, 148, 324-333.	2.8	23
62	A research pathway for the study of the delivery and disposition of nebulised antibiotics: an incremental approach from in vitro to large animal models. Intensive Care Medicine Experimental, 2018, 6, 17.	1.9	7
63	Recovery rates of combination antibiotic therapy using in vitro microdialysis simulating in vivo conditions. Journal of Pharmaceutical Analysis, 2018, 8, 407-412.	5.3	6
64	A pharmacokinetic case study of intravenous posaconazole in a critically ill patient with hypoalbuminaemia receiving continuous venovenous haemodiafiltration. International Journal of Antimicrobial Agents, 2018, 52, 506-509.	2.5	7
65	<i>Ex Vivo</i> Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	27
66	Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	54
67	Substantial Impact of Altered Pharmacokinetics in Critically III Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	34
68	Caspofungin Population Pharmacokinetics in Critically III Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration. Clinical Pharmacokinetics, 2017, 56, 1057-1068.	3.5	32
69	An LC–MS/MS method to determine vancomycin in plasma (total and unbound), urine and renal replacement therapy effluent. Bioanalysis, 2017, 9, 911-924.	1.5	17
70	A validated UHPLC–MS/MS method for the measurement of riluzole in plasma and myocardial tissue samples. Biomedical Chromatography, 2017, 31, e4030.	1.7	1
71	Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients. International Journal of Antimicrobial Agents, 2017, 50, 227-231.	2.5	20
72	Effect of Obesity on the Population Pharmacokinetics of Meropenem in Critically III Patients. Antimicrobial Agents and Chemotherapy, 2016, 60, 4577-4584.	3.2	38

#	Article	IF	CITATIONS
73	Is there a role for microsampling in antibiotic pharmacokinetic studies?. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 601-614.	3.3	20
74	Effect of Obesity on the Population Pharmacokinetics of Fluconazole in Critically III Patients. Antimicrobial Agents and Chemotherapy, 2016, 60, 6550-6557.	3.2	38
75	Effect of time on recovery of plasma microsamples for the quantitative determination of vancomycin. Bioanalysis, 2016, 8, 2235-2242.	1.5	29
76	Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis. International Journal of Antimicrobial Agents, 2016, 48, 542-546.	2.5	30
77	Stability of Antibiotics for Intraperitoneal Administration in Extraneal 7.5% Icodextrin Peritoneal Dialysis Bags (Stab Study). Peritoneal Dialysis International, 2016, 36, 421-426.	2.3	11
78	Pharmacokinetics of Piperacillin in Critically Ill Australian Indigenous Patients with Severe Sepsis. Antimicrobial Agents and Chemotherapy, 2016, 60, 7402-7406.	3.2	14
79	Total and unbound ceftriaxone pharmacokinetics in critically ill Australian Indigenous patients with severe sepsis. International Journal of Antimicrobial Agents, 2016, 48, 748-752.	2.5	22
80	Determination of Cefalothin and Cefazolin in Human Plasma, Urine and Peritoneal Dialysate by UHPLCâ€MS/MS: application to a pilot pharmacokinetic study in humans. Biomedical Chromatography, 2016, 30, 872-879.	1.7	22
81	Effect of different renal function on antibacterial effects of piperacillin against <i>Pseudomonas aeruginosa</i> evaluated via the hollow-fibre infection model and mechanism-based modelling. Journal of Antimicrobial Chemotherapy, 2016, 71, 2509-2520.	3.0	38
82	Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy. Antimicrobial Agents and Chemotherapy, 2016, 60, 4901-4909.	3.2	29
83	Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Medicine, 2016, 42, 1535-1545.	8.2	244
84	Pharmacokinetics of Intraperitoneal Cefalothin and Cefazolin in Patients Being Treated for Peritoneal Dialysis-Associated Peritonitis. Peritoneal Dialysis International, 2016, 36, 415-420.	2.3	7
85	SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patients. BMC Infectious Diseases, 2016, 16, 103.	2.9	14
86	Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients. Journal of Antimicrobial Chemotherapy, 2016, 71, 1643-1650.	3.0	16
87	Pharmacokinetics of a novel dosing regimen of oral melatonin in critically ill patients. Clinical Chemistry and Laboratory Medicine, 2016, 54, 467-72.	2.3	19
88	Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. Journal of Antimicrobial Chemotherapy, 2016, 71, 196-207.	3.0	129
89	Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit. Antimicrobial Agents and Chemotherapy, 2016, 60, 206-214.	3.2	11
90	Can We Use an Ex Vivo Continuous Hemofiltration Model to Describe the Adsorption and Elimination of Meropenem and Piperacillin?. International Journal of Artificial Organs, 2015, 38, 419-424.	1.4	13

#	Article	IF	Citations
91	Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?. Critical Care, 2015, 19, 28.	5.8	111
92	Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study. Critical Care, 2015, 19, 164.	5.8	181
93	Quantitative bioanalytical validation of fosfomycin in human whole blood with volumetric absorptive microsampling. Bioanalysis, 2015, 7, 2585-2595.	1.5	45
94	Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models. Critical Care, 2015, 19, 437.	5.8	67
95	Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration. International Journal of Antimicrobial Agents, 2015, 45, 41-45.	2.5	50
96	Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?. Journal of Antimicrobial Chemotherapy, 2015, 70, 528-533.	3.0	21
97	Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 1495-1502.	3.0	60
98	Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study. Critical Care, 2015, 19, 33.	5.8	108
99	Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration. International Journal of Antimicrobial Agents, 2015, 46, 39-44.	2.5	28
100	A validated method for the quantification of fosfomycin on dried plasma spots by HPLC–MS/MS: Application to a pilot pharmacokinetic study in humans. Journal of Pharmaceutical and Biomedical Analysis, 2015, 115, 509-514.	2.8	23
101	An UHPLC–MS/MS method for the simultaneous determination of ampicillin and sulbactam in human plasma and urine. Bioanalysis, 2015, 7, 2311-2319.	1.5	9
102	Assays for therapeutic drug monitoring of \hat{l}^2 -lactam antibiotics: A structured review. International Journal of Antimicrobial Agents, 2015, 46, 367-375.	2.5	95
103	Population Pharmacokinetics of Fosfomycin in Critically III Patients. Antimicrobial Agents and Chemotherapy, 2015, 59, 6471-6476.	3.2	59
104	A simple LC–MS/MS method using HILIC chromatography for the determination of fosfomycin in plasma and urine: Application to a pilot pharmacokinetic study in humans. Journal of Pharmaceutical and Biomedical Analysis, 2015, 105, 39-45.	2.8	28
105	The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study. Critical Care, 2014, 18, 565.	5.8	87
106	Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds. Critical Care, 2014, 18, 657.	5.8	64
107	Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration. Journal of Antimicrobial Chemotherapy, 2014, 69, 2508-2516.	3.0	29
108	DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current Â-Lactam Antibiotic Doses Sufficient for Critically III Patients?. Clinical Infectious Diseases, 2014, 58, 1072-1083.	5.8	843

#	Article	IF	CITATIONS
109	Reply to Rhodes et al. Clinical Infectious Diseases, 2014, 59, 907-908.	5.8	2
110	Risk factors for target non-attainment during empirical treatment with \hat{l}^2 -lactam antibiotics in critically ill patients. Intensive Care Medicine, 2014, 40, 1340-1351.	8.2	147
111	Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. Critical Care, 2014, 18, R99.	5.8	87
112	Pharmacokinetics of meropenem and piperacillin in critically ill patients with indwelling surgical drains. International Journal of Antimicrobial Agents, 2013, 42, 90-93.	2.5	24
113	Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?. Critical Care, 2013, 17, R84.	5.8	166
114	Altered antibiotic pharmacokinetics during extracorporeal membrane oxygenation: cause for concern?. Journal of Antimicrobial Chemotherapy, 2013, 68, 726-727.	3.0	42
115	Propylene Glycol and Glycerol Concentration in Ultrasound Gel. Regional Anesthesia and Pain Medicine, 2013, 38, 75-76.	2.3	2
116	Pharmacokinetics of Intraperitoneal Gentamicin in Peritoneal Dialysis Patients with Peritonitis (GIPD) Tj ETQq0 C) 0 rgBT /C	verlock 10 Tf
117	Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. Critical Care, 2012, 16, R194.	5.8	233
118	ASAP ECMO: Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: a multi-centre study to optimise drug therapy during ECMO. BMC Anesthesiology, 2012, 12, 29.	1.8	90
119	DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. BMC Infectious Diseases, 2012, 12, 152.	2.9	47
120	Development of simulated and ovine models of extracorporeal life support to improve understanding of circuit-host interactions. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2012, 14, 105-11.	0.1	19
121	Plasma and Tissue Pharmacokinetics of Cefazolin in Patients Undergoing Elective and Semielective Abdominal Aortic Aneurysm Open Repair Surgery. Antimicrobial Agents and Chemotherapy, 2011, 55, 5238-5242.	3.2	68
122	Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 2039-2043.	2.3	172
123	Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. Journal of Antimicrobial Chemotherapy, 2010, 65, 1771-1778.	3.0	102
124	Meropenem Dosing in Critically Ill Patients with Sepsis Receiving High-Volume Continuous Venovenous Hemofiltration. Antimicrobial Agents and Chemotherapy, 2010, 54, 2974-2978.	3.2	67
125	Cefepime Versus Cefpirome: The Importance of Creatinine Clearance. Anesthesia and Analgesia, 2003, 97, 1149-1154.	2.2	81
126	Intravascular administration sets are accurate and in appropriate condition after 7 days of continuous use: an in vitro study. Journal of Advanced Nursing, 2002, 37, 330-337.	3.3	12

#	Article	IF	CITATION
127	Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. Intensive Care Medicine, 2001, 27, 363-370.	8.2	69
128	Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration. Intensive Care Medicine, 2001, 27, 665-672.	8.2	47
129	Cerebrospinal Fluid Penetration of High Doses of Intravenous Ciprofloxacin in Meningitis. Clinical Infectious Diseases, 2000, 31, 1131-1133.	5.8	51
130	Co-administration of sub-antinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced CNS side-effects in rats. Pain, 2000, 84, 421-428.	4.2	75
131	Low Plasma Cefepime Levels in Critically Ill Septic Patients: Pharmacokinetic Modeling Indicates Improved Troughs with Revised Dosing. Antimicrobial Agents and Chemotherapy, 1999, 43, 2559-2561.	3.2	115
132	Accuracy of pleural fluid pH and PCO ₂ measurement in a blood gas analyser. Analysis of bias and precision. Scandinavian Journal of Clinical and Laboratory Investigation, 1999, 59, 619-626.	1.2	8
133	Copper(II) complexes of the fluoroquinolone antimicrobial ciprofloxacin. Synthesis, X-ray structural characterization, and potentiometric study. Journal of Inorganic Biochemistry, 1996, 62, 1-16.	3.5	112
134	Interaction of Norfloxacin with Divalent and Trivalent Pharmaceutical Cations. In Vitro Complexation and in Vivo Pharmacokinetic Studies in the Dog. Journal of Pharmaceutical Sciences, 1996, 85, 803-809.	3.3	56
135	Rapid and economical high-performance liquid chromatographic method for the determination of norfloxacin in serum using a microparticulate C18 guard cartridge. Biomedical Applications, 1995, 674, 306-309.	1.7	25
136	Synthesis and X-ray structural characterization of an iron(III) complex of the fluoroquinolone antimicrobial ciprofloxacin, [Fe(CIP)(NTA)]3·5H2O (NTANitrilotriacetato). Polyhedron, 1995, 14, 2835-2840.	2.2	45
137	Spectroscopic and ligand-field analysis of the spin–orbit interaction between the1Egand3T2gstates in bis(1,4,7-triazacyclononane)nickel(II). Journal of the Chemical Society Dalton Transactions, 1992, , 2971-2976.	1.1	22
138	Plasma and Interstitial Fluid Pharmacokinetics of Prophylactic Cefazolin in Elective Bariatric Surgery Patients. Antimicrobial Agents and Chemotherapy, 0, , .	3.2	4